Skip to main content
. 2022 Nov 17;23(22):14242. doi: 10.3390/ijms232214242

Figure 1.

Figure 1

(a) Association of estrogen and progesterone receptor immunoexpression between primary and recurrent tumors (Immuno-reactive Score System); (b) Association of estrogen and progesterone receptor immunoexpression between primary and recurrent tumors (Allred Total Score System). (a) shows the distribution of Immunoreactive Score for estrogen and progesterone receptor expression in primary and paired recurrent HGSOC. ER, estrogen receptor; PR, progesterone receptor; PT, primary tumor; RT, paired recurrent tumor; HGSOC, high-grade serous ovarian cancer; IRS, Immunoreactive Score. There was a statistically significant lower PR expression in chemotherapy-sensitive-matched primary and recurrent HGSOC. (b) shows the distribution of Allred Total Score for estrogen and progesterone receptor expression in primary and paired recurrent HGSOC. ER, estrogen receptor; PR, progesterone receptor; PT, primary tumor; RT, paired recurrent tumor; HGSOC, high-grade serous ovarian cancer; ATS, Allred Total score. Progesterone receptor expression was statistically significantly lower in chemotherapy-sensitive-matched primary and recurrent HGSOC.